Verification register Bio, Health & Neuro
Current reading
The readiness gap, in one scan
AI-assisted assembly · derived results
- Claimed
- 35
- Reported
- 35
- Verified
- 32
- Gap
- +3
Public ambition and stated capability
Observed practitioner reporting
Independently supported evidence
Claimed minus verified
Evidence strength Strong
Decision
What the current evidence supports
Human editorial judgment · 2026-06-28
Too early to adopt
- Why
- First-in-human dosing plus a $80M Series D (Apr 2026) make this a genuine milestone, but it is an 18-patient Phase 1 safety trial of a modality whose central oncogenic-vs-rejuvenation risk is still unresolved in the literature; nothing is adoptable, only watchable
- Next
- Track the NCT07290244 Day-112 safety / dose-limiting-toxicity readout (primary completion ~May 2027) and any exploratory visual-function signal; do not treat partial reprogramming as a deployable modality until a clean human safety window is demonstrated
Constraints
Blockers
No named blocker is present in the current public projection.
Evidence summary
Derived counts
AI-assisted assembly
- Total
- 7
- Tier 1
- 0
- Tier 2
- 0
- Tier 3
- 7
- Supports
- 3
- Contradicts
- 1
- Context
- 3
- Latest observed
- 2026-06-09
Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.
Publication record
Revisions
Initial public reading
This is the initial public reading. No earlier readiness change is recorded.